New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
This study compared approximately 390,000 people who received the Company’s single-shot COVID-19 vaccine versus approximately 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity.This study is a longitudinal cohort design, using robust propensity matching methods to create a comparator cohort to assess real-world VE. All analyses were performed using the Aetion Evidence Platform, which is a scientifically validated software that is also used by regulators, payers, and health technology assessment bodies to assess the safety,...
Source: Johnson and Johnson - September 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catal...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral present...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
New Brunswick, NJ (September 16 th, 2021) - Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 19th to review third-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer will host the call. The question and answer portion of the call will also include: Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices; Jennifer Taubert, Executive Vice President, Worldwide Chairman Pharmaceuticals and Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer Health. Investors and other interested pa...
Source: Johnson and Johnson - September 16, 2021 Category: Pharmaceuticals Tags: Financial Source Type: news

Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases
NEW BRUNSWICK, N.J., September 13, 2021 – Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), generated robust humoral (antibody) immune responses in adults and children (ages 1-17) with the immune responses persisting in adults for at least two years. The data also showed that booster vaccination with Ad26.ZEBOV, administered to adults two years after the initial vaccination, induced a strong anamnestic (immune) response within seven days. These findings support the p...
Source: Johnson and Johnson - September 13, 2021 Category: Pharmaceuticals Source Type: news

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA a...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
This study is being conducted in the Americas and Europe where different strains of HIV are circulating. Given these differentiating factors and following consultations with the Mosaico study independent Data and Safety Monitoring Board (DSMB), it was decided that the Mosaico study will continue at this time. “We are extremely grateful to the women who volunteered for the Imbokodo study, and to our partners, including the people on the frontlines, all of whom are contributing every day to this enduring quest to make HIV history,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scien...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson to Participate in the Cantor Virtual Global Healthcare Conference
New Brunswick, N.J., August 26, 2021 -- Johnson & Johnson (NYSE: JNJ) will participate in the Cantor Virtual Global Healthcare Conference on Tuesday, September 28th. Mathai Mammen, Global Head, Research & Development Janssen Research Development and Scott White, Company Group Chairman NA Pharmaceuticals will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately 48-hrs after the live webcast. ### (Source: Johnson and Johnson)
Source: Johnson and Johnson - August 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Seeks Global Nominees for Award Geared at Female Researchers Working in Science, Technology, Engineering, Math, Manufacturing and Design
New Brunswick, N.J. – August 26, 2021 – Johnson & Johnson (NYSE: JNJ) today announced it is accepting applications for its 2022 Women in STEM2D (WiSTEM2D) Scholars Award. The award, which aims to support assistant or associate academic professors in the disciplines of Science, Technology, Engineering, Math, Manufacturing and Design, provides recipients with three years of mentorship from leaders at Johnson & Johnson and a total $150,000 ($50,000 each year). The deadline for applications is September 27, 2021 at 9 a.m. HST, and guidelines and additional details are available here: https://www.jnj.com/wis...
Source: Johnson and Johnson - August 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

DePuy Synthes to Showcase Innovation Momentum at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting
Raynham, Mass., Aug. 25, 2021 -- The Johnson & Johnson Medical Devices Companies* announced that DePuy Synthes,** The Orthopaedics Company of Johnson & Johnson, will feature new products and technology solutions shaping new standards of care for modern day orthopaedics during the American Academy of Orthopaedic Surgeons (AAOS) annual meeting Aug. 31–Sept. 3 in San Diego. From robotics and more personalized implants to connected instrumentation, advanced imaging and visualization technology, DePuy Synthes will showcase next generation product innovations spanning its VELYS™ Digital Surgery, Hip, Knee, Sh...
Source: Johnson and Johnson - August 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
NEW BRUNSWICK, N.J., August 25, 2021 – Johnson & Johnson today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine. In July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization. In anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals...
Source: Johnson and Johnson - August 25, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) e...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Alex Gorsky to Serve as Executive Chairman and Transition Role of Chief Executive Officer of Johnson & Johnson to Joaquin Duato, Effective January 3, 2022
New Brunswick, N.J. (August 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced that Mr. Alex Gorsky, currently Chairman and Chief Executive Officer, will serve as Executive Chairman of Johnson & Johnson and transition the Chief Executive Officer role to Mr. Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, effective January 3, 2022. Following the transition of the Chief Executive Officer role, Mr. Duato will also be appointed as a member of the Company’s Board of Directors. “It has been an honor and privilege to lead this company as Chairman and CEO for near...
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine
NEW BRUNSWICK, N.J., August 18, 2021 -- We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 vaccine.In July, Johnson & Johnson shared data demonstrating that our single-shot COVID-19 vaccine generated strong, persistent immune activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. Interim results from a Phase 1/2a study published in the New England Journal of Medicine also showed that the durability of the immune response was strong, with no waning for at least e...
Source: Johnson and Johnson - August 18, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

DePuy Synthes Introduces the INHANCE ™ Shoulder System, a First-to-Market, Fully Integrated Shoulder Arthroplasty System
RAYNHAM, MA – August 18, 2021 – Today, The Johnson & Johnson Medical Devices Companies* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson,** introduces the INHANCE™ Shoulder System, a first-to-market, fully integrated shoulder arthroplasty system. The system is designed with an intuitive stemless-first surgical approach that aligns with how surgeons approach patient care. The INHANCE Shoulder System is the first shoulder system to offer surgeons the ability to seamlessly transition from stemless to stemmed implants during surgical procedures. There are many reasons surgeo...
Source: Johnson and Johnson - August 18, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
New Brunswick, NJ (August 12, 2021) -- Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15th. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Mathai Mammen, Global Head, Research & Development Janssen Research Development will represent the Company in a session scheduled at 9:30 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately 48-hrs after the l...
Source: Johnson and Johnson - August 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Ethicon ’s Echelon Circular Powered Stapler Associated With Major Reduction In Serious Complications Following Colorectal Surgery
Cinncinnati, OH – Aug. 11, 2021 – Ethicon*, part of the Johnson & Johnson Medical Devices Companies**, today announced the results of a new real-world study that shows its ECHELON CIRCULAR Powered Stapler was associated with a 74% reduction in anastomotic leak rates (1.8% vs. 6.9%)[1] and a 44% reduction in 30-day inpatient hospital readmission rates (6.1% vs.10.8%) after colorectal surgery compared with manual circular staplers.[2]The study, published in Surgical Endoscopy, shows the groundbreaking device is just as effective in reducing life-threatening and costly surgical complications in real-world surg...
Source: Johnson and Johnson - August 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson to Participate in Barclays Global Consumer Staples Virtual Conference
New Brunswick, NJ (August 9, 2021) -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Virtual Conference on Friday, September 10th. Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer Health will represent the Company in a session scheduled at 9:20 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately 48-hours after the live webcast.### (Source: Johnson and Johnson)
Source: Johnson and Johnson - August 9, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

UPTRAVI ® (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)
TITUSVILLE, N.J. – July 30, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved UPTRAVI® (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy. UPTRAVI® IV is a therapeutic option that will allow patients to avoid short-term treatment interruptions and stay on UPTRAVI® therapy, as uninterrupted treatment is considered key for individ...
Source: Johnson and Johnson - July 30, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Statement on U.S. FDA Approval of Shelf Life Extension for Company ’s COVID-19 Vaccine
NEW BRUNSWICK, N.J., July 28, 2021 -- We are pleased to confirm the U.S. Food & Drug Administration (FDA) has extended the shelf life for the Johnson & Johnson single-shot COVID-19 vaccine to six months. The decision is based on data from ongoing stability assessment studies, which have demonstrated the vaccine is stable at six months when refrigerated at temperatures of 36 – 46 degrees Fahrenheit (2 – 8 degrees Celsius). Expiration dates will be updated on www.vaxcheck.jnj, where vaccine providers can confirm the latest expiration dates of our vaccine.Evidence has demonstrated that Johnson & Johnso...
Source: Johnson and Johnson - July 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson to Participate in the Virtual Wells Fargo Healthcare Conference
New Brunswick, NJ (July 27th, 2021) -- Johnson & Johnson (NYSE: JNJ) will participate in the Virtual Wells Fargo Healthcare Conference on Friday, September 10th. Joaquin Duato, Vice Chairman of the Executive Committee will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately 48-hours after the live webcast.### (Source: Johnson and Johnson)
Source: Johnson and Johnson - July 27, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Statement on Nationwide Opioid Settlement Agreement
NEW BRUNSWICK, N.J., July 21, 2021 - Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies today announced the finalization of a nationwide settlement agreement to resolve opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States. As previously announced, the Company will contribute up to $5 billion to the settlement, depending on the number of state and local governments that elect to opt into the agreement over the next several months. "We recognize the opioid crisis is a tremendously complex public health issue, and we have deep sympathy for ev...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

DePuy Synthes Unveils VELYS ™ Robotic-Assisted Solution In Australia: The Next Generation Robotic-Assisted Solution For Knee Replacement Surgery Designed For Use With The ATTUNE® Knee System
Sydney, Australia, July 20, 2021 -- DePuy Synthes, the orthopaedics company of Johnson & Johnson, today announced that Australian orthopaedic surgeons will be among the first in the world to access the next generation of robotics. The VELYS™ Robotic-Assisted Solution, indicated for use with the ATTUNE® Knee System for total knee arthroplasty, has recently been included on the Australian Register of Therapeutic Goods (ARTG).Sue Martin, Managing Director of Johnson & Johnson Medical Australia and New Zealand says: “Australia joins an exclusive list of just a few countries with access to this technolog...
Source: Johnson and Johnson - July 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2021
New Brunswick, NJ (July 19, 2021) – Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2021 of $1.06 per share on the company’s common stock. The dividend is payable on September 7, 2021 to shareholders of record at the close of business on August 24, 2021. The ex-dividend date is August 23, 2021.About Johnson & JohnsonAt Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and eve...
Source: Johnson and Johnson - July 19, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Innovation Announces Extension Of Innovation Partnering Office at Monash University In Collaboration With Victorian State Government To Accelerate The Life-Sciences Hub
MELBOURNE, Australia, July 15, 2021 -- Johnson & Johnson Innovation announced today the extension of the Johnson & Johnson Innovation Partnering Office at Monash University's Clayton Campus in Melbourne (JJIPO@Monash) in collaboration with the Victorian State Government.This joint initiative between Johnson & Johnson Innovation, the Victorian Government and Monash University will be extended for approximately two years through June 30, 2023. The agreement will allow JJIPO@Monash to continue connecting with the Victorian innovation ecosystem, nurturing and accelerating innovative research, new product developmen...
Source: Johnson and Johnson - July 15, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., July 14, 2021 – Interim results from a Phase 1/2a sub-study published in the New England Journal of Medicine (NEJM) demonstrated that both humoral (antibody) and cellular (T-cell) immune responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization, the length of time evaluated to date. Data showed that T-cell responses – including the important CD8+ T-cells that seek out and destroy infected cells – persisted over the eight-month timeframe examined. The Company announced topline preprint study results from...
Source: Johnson and Johnson - July 14, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA ® and AVEENO® Aerosol Sunscreen Products Due to the Presence of Benzene
NEW BRUNSWICK, N.J., JULY 14, 2021 – Johnson & Johnson Consumer Inc. (JJCI) is voluntarily recalling all lots of five NEUTROGENA® and AVEENO® aerosol sunscreen product lines to the consumer level. Internal testing identified low levels of benzene in some samples of the products. Consumers should stop using the affected products and follow the instructions set forth below.The only sunscreen products impacted are aerosol products, specifically: NEUTROGENA® Beach Defense® aerosol sunscreen, NEUTROGENA® Cool Dry Sport aerosol sunscreen,NEUTROGENA® Invisible Daily™ defense aerosol sunscre...
Source: Johnson and Johnson - July 14, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Statement on COVID-19 Vaccine (7/12)
NEW BRUNSWICK, N.J., July 12, 2021 – The safety and well-being of the people who use our products is our number one priority. Rare cases of the neurological disorder, Guillain-Barré syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination. While the chance of having this occur is very low, Johnson & Johnson has updated its COVID-19 Vaccine Factsheet to include important information about these rare cases and on the signs and symptoms of Guillain-Barré syndrome. Updates with this new information will be implemented in other regions...
Source: Johnson and Johnson - July 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Statement on U.S. Government Donations of Company ’s COVID-19 Vaccine
NEW BRUNSWICK, N.J., July 9, 2021 – Johnson & Johnson welcomes the U.S. government’s decision to donate an initial 12 million doses of the Company’s COVID-19 vaccine through the COVAX Facility. The United States is sharing the doses via COVAX to multiple lower-income countries across three continents. The first shipment of 1.5 million doses arrived in Afghanistan on July 9, 2021. In the coming weeks, it is anticipated that the U.S. will allocate a second tranche of Johnson & Johnson COVID-19 vaccines to additional lower-income countries. Separately, the U.S. has already donated 8 million doses of ...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being pr...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Launches Network of Global Health Discovery Centers that Aim to Speed Up Science and Tackle Pandemic Threats
NEW BRUNSWICK, N.J., July 9, 2021 – Johnson & Johnson (the Company) today announced the launch of the J&J Centers for Global Health Discovery (J&J Centers), a new, global network of unique research partnerships that will leverage the institutional strengths of Johnson & Johnson and leading academic institutions to accelerate discovery research to address the world’s most pressing global health challenges. The first J&J Satellite Center for Global Health Discovery (Satellite Center) was launched at the London School of Hygiene & Tropical Medicine (LSHTM) at an event co-hosted by Johnson &...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine ...
Source: Johnson and Johnson - July 1, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reaches Opioid Settlement Agreement with New York State Consistent with Terms of Previously Announced Broader Settlement Agreement in Principle
June 26, 2021 – Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies today announced a settlement agreement with the State of New York and its participating subdivisions, including Nassau County and Suffolk County, resolving their opioid-related claims against the Company. With this agreement, the Company is removed from the trial scheduled to begin in Suffolk County on June 28, 2021. The settlement will provide New York and its participating subdivisions with up to $263 million in funding to address opioid related issues, as well as reimbursement for attorney fees and costs. The settlement is no...
Source: Johnson and Johnson - June 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Medical Announces Strategic Partnership With Aussie Startup Navbit To Bring Smartphone-Inspired Tech To Hip Replacement Surgery
Sydney, Australia, June 24, 2021 – DePuy Synthes in Australia, a business unit of Johnson & Johnson Medical Pty Ltd, today announced it has entered into an exclusive agreement with Australian start-up Navbit to introduce the Navbit Sprint into operating theatres across the country. The Australian-made innovation is a compact, single use medical device designed to assist surgeons in placing and aligning the acetabular cup, a component that is placed into the hip socket during joint replacement surgery. It uses smartphone-like GPS technology to provide real-time feedback to the surgeon on the position of the cup th...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with co...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Ethicon Expands Advanced Biopolar Energy Portfolio With Launch Of Enseal X1 Curved Jaw Tissue Sealer
CINCINNATI, OH – June 21, 2021 -- Ethicon*, part of the Johnson & Johnson Medical Devices Companies,** today announced the launch of the ENSEAL X1 Curved Jaw Tissue Sealer, a new advanced bipolar energy device that increases procedural efficiency[1] and provided stronger sealing[2] and better access to more tissue than LigaSure™ Maryland.[3] The device is indicated for colorectal, gynecological, bariatric surgery and thoracic procedures. The ENSEAL X1 Curved Jaw is the first of several new advanced laparoscopic bipolar devices the company plans to launch in the coming months as it expands its extensive ener...
Source: Johnson and Johnson - June 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Statement on Supply of its Single-shot COVID-19 Vaccine
New Brunswick, N.J., June 11, 2021 – Johnson & Johnson confirms the United States Food & Drug Administration (FDA) has authorized two batches of drug substance, manufactured at the Emergent BioSolutions, Inc. Bayview facility, under the Emergency Use Authorization (EUA) for its single-shot COVID-19 vaccine. “Since establishing our COVID-19 vaccine program, Johnson & Johnson has committed to producing safe, high-quality vaccines in order to bring health and hope to people everywhere,” said Kathy Wengel, Executive Vice President and Chief Global Supply Chain Officer, Johnson & Johnson. &ldqu...
Source: Johnson and Johnson - June 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Six Global Winners for the 2021 Women in STEM2D Scholar Awards
New Brunswick, N.J., June 11, 2021 – Johnson & Johnson announced today its prestigious Women in STEM2D (WiSTEM2D) Scholar Award recipients, marking the fifth year since the Awards’ inception. The program recognizes one scholar in each STEM2D discipline: Science, Technology, Engineering, Math, Manufacturing and Design, and provides each recipient with $150,000 in research funding and three years of mentorship from Johnson & Johnson. Six diverse, international female recipients were selected out of a competitive global applicant pool that garnered more than 650 applications from 40 countries. Launched in ...
Source: Johnson and Johnson - June 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Statement on FDA Approval of Shelf Life Extension for Company ’s COVID-19 Vaccine
NEW BRUNSWICK, N.J., June 10, 2021 -- We are pleased to confirm the U.S. Food & Drug Administration (FDA) has authorized an extension of the shelf life for the Johnson & Johnson single-shot COVID-19 vaccine from 3 months to 4.5 months. The decision is based on data from ongoing stability assessment studies, which have demonstrated that the vaccine is stable at 4.5 months when refrigerated at temperatures of 36 – 46 degrees Fahrenheit (2 – 8 degrees Celsius). Expiration dates will be updated on www.vaxcheck.jnj. Vaccine providers should visit www.vaxcheck.jnj to confirm the latest expiration dates of our...
Source: Johnson and Johnson - June 10, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
New Brunswick, NJ (June 9th, 2021) - Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 21st to review second-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Christopher DelOrefice, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include Alex Gorsky, Chairman and Chief Executive Officer.Investors and other interested parties can access the webcast/conference call in the following ways:The webcast and presentation material are accessible at Johnson &am...
Source: Johnson and Johnson - June 9, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Releases 2020 Health for Humanity Report Highlighting Performance and Progress on Environmental, Social and Governance Priorities
NEW BRUNSWICK, N.J., June 9, 2021 – Johnson & Johnson (NYSE: JNJ) today published the 2020 Health for Humanity Report (Report), which serves as the Company’s annual disclosure on environmental, social and governance (ESG) performance and illustrates progress toward fulfilling its corporate purpose to change the trajectory of health for humanity. The Report documents the Company’s performance and provides information on how the Company generates long-term social, environmental and economic value for all stakeholders; provides an accounting of the final year of progress against the Johnson & Johnson...
Source: Johnson and Johnson - June 9, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news